Iressa Expanded Access Program (EAP)

Exclusion Criteria

• Any of the following will exclude a patient from entering the trial:
• * receiving concurrent radiotherapy, chemotherapy, or other systemic anti-cancer medication or any other investigational agent. * Non-cytotoxic or hormonal therapies for the adjuvant treatment of cancer or for previously treated cancers may be allowed per AstraZeneca permission;
• * patients eligible for or previously enrolled on a ZD1839 blinded clinical trial protocol. Patients eligible for or previously enrolled on an open-label or unblinded ZD1839 clinical trial may be considered for acceptance into the Expanded Access Program with AstraZeneca permission;
• * having other active malignancies;
• * incomplete healing from previous oncologic or other major surgery;
• * evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial;
• * pregnancy or breast feeding (women of child-bearing potential).